医学
普罗布考
家族性高胆固醇血症
内科学
冠状动脉疾病
Evolocumab公司
复合杂合度
胃肠病学
皮肤病科
胆固醇
遗传学
等位基因
脂蛋白
生物
基因
载脂蛋白A1
作者
Hayato Tada,Nobuko Kojima,Kan Yamagami,Masayuki Takamura,Masa–aki Kawashiri
标识
DOI:10.1016/j.cca.2022.02.021
摘要
Clinical manifestations and genetic backgrounds of Japanese patients with sitosterolemia have been unclear.We searched PubMed for studies using the keywords "sitosterolemia" or "phytosterolemia" and "Japan". Moreover, we added information from the members of the Committee on Primary Dyslipidemia under the Research Program on Rare and Intractable Disease of the Ministry of Health, Labour and Welfare (MHLW) of Japan.We identified 36 patients with sitosterolemia caused by biallelic pathogenic mutations in the ATP-binding cassette subfamily G member 5 (ABCG5) or ATP-binding cassette subfamily G member 8 (ABCG8) from 31 families in Japan. The diagnosed age ranged from 0 to 64 years (median 13 years). The median sitosterol and LDL cholesterol levels were 100 μg/ml (IQR: 50-183), and 193 mg/dl (IQR: 108-295), respectively. All the patients exhibited cutaneous and/or tendon xanthomas, up to 9 (25%) patients exhibited premature coronary artery disease, 5 (16%) patients exhibited arthritis, and 8 (22%) patients exhibited blood abnormalities. Ezetimibe was administered to all the patients, including infantile cases, while statins, colestimide, evolocumab, probucol, and LDL apheresis were also used.We are providing a demographic overview of the clinical and genetic backgrounds of Japanese patients with sitosterolemia.
科研通智能强力驱动
Strongly Powered by AbleSci AI